^
    Apply
    Study of Ribociclib and Everolimus in HGG and DIPG (NCT05843253)
    Phase 2
    Nationwide Children's Hospital
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/22/2024
    Primary completion :
    08/28/2028
    Completion :
    08/28/2034
    PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C
    |
    PIK3CA mutation • CDKN2A deletion
    |
    everolimus • Kisqali (ribociclib)
    A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (NCT04145115)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/17/2025
    Initiation :
    12/24/2020
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX
    |
    TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) (NCT04116541)
    Phase 2
    Centre Leon Berard
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/28/2020
    Primary completion :
    02/01/2026
    Completion :
    11/01/2026
    KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK
    |
    KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)
    Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients (NCT02933736)
    Phase 1
    Nader Sanai
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    10/01/2016
    Primary completion :
    03/01/2023
    Completion :
    01/01/2025
    CDKN2A • CCND1 • CDK4 • CDKN2B
    |
    CDKN2A deletion
    |
    Kisqali (ribociclib)
    Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) (NCT02546661)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/03/2016
    Primary completion :
    03/18/2020
    Completion :
    06/28/2024
    HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (NCT05538572)
    Phase 1
    Prelude Therapeutics
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    12/27/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B
    |
    KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type
    |
    PRT3645
    A Study of Abemaciclib in Recurrent Glioblastoma (NCT02981940)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    07/27/2023
    Initiation :
    02/09/2017
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    CDKN2A • RB1 • CDK4 • CDKN2B • CDK6
    |
    CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type
    |
    Verzenio (abemaciclib)
    Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) (NCT03356223)
    Phase 2
    Centre Leon Berard
    Completed
    Last update posted :
    02/23/2023
    Initiation :
    02/05/2018
    Primary completion :
    11/05/2022
    Completion :
    12/05/2022
    CDKN2A • CCND1
    |
    CDKN2A deletion • CCND1 amplification • CDK4 amplification
    |
    Erbitux (cetuximab) • Verzenio (abemaciclib)
    Abemaciclib + Pembrolizumab In Glioblastoma (NCT04118036)
    Phase 2
    Dana-Farber Cancer Institute
    Withdrawn
    Last update posted :
    12/14/2021
    Initiation :
    12/01/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    CDKN2A • RB1 • CDKN2B • CASP3
    |
    CDKN2A deletion • RB1 wild-type
    |
    Keytruda (pembrolizumab) • Verzenio (abemaciclib)
    Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST) (NCT01907607)
    Phase 2
    Institut Bergonié
    Completed
    Last update posted :
    01/20/2021
    Initiation :
    02/01/2014
    Primary completion :
    12/01/2016
    Completion :
    02/01/2019
    KIT • CDKN2A • PDGFRA • ANO1
    |
    CDKN2A deletion • PDGFRA mutation
    |
    Ibrance (palbociclib) • imatinib • sunitinib
    Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM) (NCT04183569)
    Phase N/A
    University Hospital, Bordeaux
    Unknown status
    Last update posted :
    04/29/2020
    Initiation :
    02/19/2019
    Primary completion :
    05/01/2020
    Completion :
    05/01/2020
    BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
    |
    CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation
    Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery (NCT02540876)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    04/22/2019
    Initiation :
    09/08/2015
    Primary completion :
    02/08/2019
    Completion :
    02/08/2019
    CDKN2A
    |
    CDKN2A deletion • CDKN2A mutation
    |
    ilorasertib (ABT348)